Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

2.50
Hdl Handle:
http://hdl.handle.net/10541/78448
Title:
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).
Authors:
Davidson, Emma J; Faulkner, Rebecca L; Sehr, Peter; Pawlita, Michael; Smyth, Lucy J C; Burt, Deborah J; Tomlinson, Anne E; Hickling, Julian K; Kitchener, Henry C; Stern, Peter L
Abstract:
Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.
Affiliation:
Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). 2004, 22 (21-22):2722-9 Vaccine
Journal:
Vaccine
Issue Date:
29-Jul-2004
URI:
http://hdl.handle.net/10541/78448
DOI:
10.1016/j.vaccine.2004.01.049
PubMed ID:
15246603
Type:
Article
Language:
en
ISSN:
0264-410X
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorDavidson, Emma J-
dc.contributor.authorFaulkner, Rebecca L-
dc.contributor.authorSehr, Peter-
dc.contributor.authorPawlita, Michael-
dc.contributor.authorSmyth, Lucy J C-
dc.contributor.authorBurt, Deborah J-
dc.contributor.authorTomlinson, Anne E-
dc.contributor.authorHickling, Julian K-
dc.contributor.authorKitchener, Henry C-
dc.contributor.authorStern, Peter L-
dc.date.accessioned2009-08-25T11:18:20Z-
dc.date.available2009-08-25T11:18:20Z-
dc.date.issued2004-07-29-
dc.identifier.citationEffect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). 2004, 22 (21-22):2722-9 Vaccineen
dc.identifier.issn0264-410X-
dc.identifier.pmid15246603-
dc.identifier.doi10.1016/j.vaccine.2004.01.049-
dc.identifier.urihttp://hdl.handle.net/10541/78448-
dc.description.abstractHeterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshCancer Vaccines-
dc.subject.meshCell Division-
dc.subject.meshCervical Intraepithelial Neoplasia-
dc.subject.meshDNA, Viral-
dc.subject.meshEnzyme-Linked Immunosorbent Assay-
dc.subject.meshFemale-
dc.subject.meshGlutathione Transferase-
dc.subject.meshHumans-
dc.subject.meshImmunity, Cellular-
dc.subject.meshImmunization Schedule-
dc.subject.meshImmunization, Secondary-
dc.subject.meshImmunoglobulin G-
dc.subject.meshInterferon-gamma-
dc.subject.meshPapillomaviridae-
dc.subject.meshPhytohemagglutinins-
dc.subject.meshT-Lymphocytes-
dc.subject.meshVaccinia virus-
dc.subject.meshVulva-
dc.titleEffect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).en
dc.typeArticle-
dc.contributor.departmentImmunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalVaccineen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.